MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
复制标题
DOI：
10.1186/s12885-020-07098-4
复制
发表时间：
2020-06-29
期刊：
影响因子：
3.8
通讯作者：
Shiku, Hiroshi
中科院分区：
文献类型：
--
作者：
Ishihara, Mikiya;Kageyama, Shinichi;Shiku, Hiroshi
背景癌症睾丸 (CT) 抗原是癌症免疫疗法（例如癌症疫苗和转基因过继性 T 细胞疗法）的有希望的靶标。在本研究中，我们评估了三种CT抗原、黑色素瘤相关抗原A4（MAGE-A4）、纽约食管鳞状细胞癌1（NY-ESO-1）和肉瘤抗原基因（SAGE）的表达。方法通过定量实时聚合酶评估肿瘤样本中MAGE-A4、NY-ESO-1和/或SAGE抗原的表达。 链式反应（qRT-PCR）。研究入组前获得个人知情同意。结果2009年6月至2018年3月期间，共评估了21种肿瘤类型的585个样本。这些CT抗原的阳性表达率如下：MAGE-A4，34.6%（范围，30.7-38.7）； NY-ESO-1，21.0%（范围，17.2-25.1）；和 SAGE，21.8%（范围，18.5-25.4）。 MAGE-A4抗原在54.9%的食道癌、37.5%的头颈癌、35.0%的胃癌和34.2%的卵巢癌中表达； NY-ESO-1抗原在28.6%的肺癌、25.3%的食道癌和22.6%的卵巢癌中表达； SAGE抗原在35.3%的前列腺癌、32.9%的食道癌和26.3%的卵巢癌中表达。本研究中最常见的肿瘤类型是食道癌。检测214份食管癌样本中MAGE-A4、NY-ESO-1和SAGE抗原表达情况，其中三重阳性24份（11.2%），任意两份阳性58份（27.1%），任意一份阳性59份（27.6%），三阴性73份（34.1%）。结论食管癌CT抗原mRNA表达率较高 积极性。
BackgroundCancer testis (CT) antigens are promising targets for cancer immunotherapies such as cancer vaccines and genetically modified adoptive T cell therapy. In this study, we evaluated the expression of three CT antigens, melanoma-associated antigen A4 (MAGE-A4), New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) and sarcoma antigen gene (SAGE).MethodsMAGE-A4, NY-ESO-1 and/or SAGE antigen expression in tumour samples was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Informed consent was obtained from individuals prior to study enrolment.ResultsIn total, 585 samples in 21 tumour types were evaluated between June 2009 and March 2018. The positive expression rates of these CT antigens were as follows: MAGE-A4, 34.6% (range, 30.7-38.7); NY-ESO-1, 21.0% (range, 17.2-25.1); and SAGE, 21.8% (range, 18.5-25.4). The MAGE-A4 antigen was expressed in 54.9% of oesophageal cancers, 37.5% of head and neck cancers, 35.0% of gastric cancers and 34.2% of ovarian cancers; the NY-ESO-1 antigen was expressed in 28.6% of lung cancers, 25.3% of oesophageal cancers and 22.6% of ovarian cancers; and the SAGE antigen was expressed in 35.3% of prostate cancers, 32.9% of oesophageal cancers and 26.3% of ovarian cancers. The most common tumour type in this study was oesophageal cancer. MAGE-A4, NY-ESO-1 and SAGE antigen expression were assessed in 214 oesophageal cancer samples, among which 24 (11.2%) were triple-positive, 58 (27.1%) were positive for any two, 59 (27.6%) were positive for any one, and 73 (34.1%) were triple negative.ConclusionsOesophageal cancer exhibited a relatively high rate of CT antigen mRNA expression positivity.